Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Por Strand, Vibeke, Kremer, Joel, Wallenstein, Gene, Kanik, Keith S., Connell, Carol, Gruben, David, Zwillich, Samuel H., Fleischmann, Roy
Publicado no Arthritis Res Ther (2015)

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

Por van der Heijde, Désirée, Deodhar, Atul, Wei, James C, Drescher, Edit, Fleishaker, Dona, Hendrikx, Thijs, Li, David, Menon, Sujatha, Kanik, Keith S
Publicado no Ann Rheum Dis (2017)

Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients

Por Maksymowych, Walter P, van der Heijde, Désirée, Baraliakos, Xenofon, Deodhar, Atul, Sherlock, Sarah P, Li, David, Fleishaker, Dona, Hendrikx, Thijs, Kanik, Keith S
Publicado no Rheumatology (Oxford) (2018)

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies

Por Fleischmann, Roy, Kremer, Joel, Tanaka, Yoshiya, Gruben, David, Kanik, Keith, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene, Wilkinson, Bethanie, Zwillich, Samuel H., Keystone, Edward
Publicado no Int J Rheum Dis (2016)

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Por Helliwell, Philip, Coates, Laura C., FitzGerald, Oliver, Nash, Peter, Soriano, Enrique R., Elaine Husni, M., Hsu, Ming-Ann, Kanik, Keith S., Hendrikx, Thijs, Wu, Joseph, Kudlacz, Elizabeth
Publicado no Arthritis Res Ther (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies

Por Nash, Peter, Coates, Laura C., Fleischmann, Roy, Papp, Kim A., Gomez-Reino, Juan Jesus, Kanik, Keith S., Wang, Cunshan, Wu, Joseph, Menon, Sujatha, Hendrikx, Thijs, Ports, William C.
Publicado no Rheumatol Ther (2018)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis

Por Veale, Douglas J, McGonagle, Dennis, McInnes, Iain B, Krueger, James G, Ritchlin, Christopher T, Elewaut, Dirk, Kanik, Keith S, Hendrikx, Thijs, Berstein, Gabriel, Hodge, Jennifer, Telliez, Jean-Baptiste
Publicado no Rheumatology (Oxford) (2019)